Gyre Therapeutics (GYRE) Competitors $7.16 -0.45 (-5.91%) Closing price 04:00 PM EasternExtended Trading$7.29 +0.13 (+1.80%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE vs. KYMR, IMVT, MOR, CRNX, ALVO, HCM, AMRX, CPRX, BHC, and OGNShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Kymera Therapeutics (KYMR), Immunovant (IMVT), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Its Competitors Kymera Therapeutics Immunovant MorphoSys Crinetics Pharmaceuticals Alvotech HUTCHMED Amneal Pharmaceuticals Catalyst Pharmaceuticals Bausch Health Cos Organon & Co. Kymera Therapeutics (NASDAQ:KYMR) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment. Do institutionals and insiders hold more shares of KYMR or GYRE? 24.0% of Gyre Therapeutics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 10.0% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is KYMR or GYRE more profitable? Gyre Therapeutics has a net margin of 7.20% compared to Kymera Therapeutics' net margin of -409.07%. Gyre Therapeutics' return on equity of 9.73% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-409.07% -30.11% -25.65% Gyre Therapeutics 7.20%9.73%7.66% Do analysts prefer KYMR or GYRE? Kymera Therapeutics currently has a consensus price target of $59.11, suggesting a potential upside of 31.62%. Given Kymera Therapeutics' higher probable upside, research analysts clearly believe Kymera Therapeutics is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.00Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, KYMR or GYRE? Kymera Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Which has preferable valuation & earnings, KYMR or GYRE? Gyre Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M62.13-$223.86M-$3.10-14.49Gyre Therapeutics$105.76M6.35$12.09M$0.02358.00 Does the media prefer KYMR or GYRE? In the previous week, Kymera Therapeutics had 5 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Kymera Therapeutics and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.87 beat Kymera Therapeutics' score of 0.89 indicating that Gyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryGyre Therapeutics beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$713.49M$2.97B$5.63B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E Ratio358.1820.2228.5719.57Price / Sales6.35292.98423.7594.57Price / Cash38.5343.1536.0257.93Price / Book6.827.568.135.54Net Income$12.09M-$55.11M$3.24B$257.73M7 Day Performance-11.82%7.56%2.03%0.95%1 Month Performance-10.39%11.47%8.29%10.68%1 Year Performance-48.71%0.88%28.40%15.67% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.2244 of 5 stars$7.16-5.9%N/A-43.3%$713.49M$105.76M358.1840News CoveragePositive NewsKYMRKymera Therapeutics3.1036 of 5 stars$43.81-2.2%$59.11+34.9%+6.1%$2.92B$47.07M-14.13170IMVTImmunovant1.4814 of 5 stars$16.42-3.1%$38.33+133.5%-39.2%$2.90BN/A-5.99120MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.439 of 5 stars$29.06-2.5%$71.75+146.9%-38.5%$2.79B$1.04M-7.61210ALVOAlvotech2.8617 of 5 stars$9.02-1.8%$18.00+99.6%-26.7%$2.77B$491.98M24.381,032HCMHUTCHMED1.6166 of 5 stars$15.42-2.5%$19.00+23.2%-16.3%$2.76B$630.20M0.001,811Positive NewsAMRXAmneal Pharmaceuticals2.5634 of 5 stars$8.41-0.1%$11.60+37.9%+17.1%$2.64B$2.79B-210.208,100CPRXCatalyst Pharmaceuticals4.922 of 5 stars$20.95-2.4%$32.83+56.7%+30.4%$2.62B$491.73M13.3480BHCBausch Health Cos4.2015 of 5 stars$6.88-2.5%$7.42+7.8%-14.6%$2.61B$9.63B-62.5520,700OGNOrganon & Co.4.8146 of 5 stars$9.74-2.2%$18.00+84.8%-53.9%$2.59B$6.40B3.384,000Trending News Related Companies and Tools Related Companies Kymera Therapeutics Competitors Immunovant Competitors MorphoSys Competitors Crinetics Pharmaceuticals Competitors Alvotech Competitors HUTCHMED Competitors Amneal Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Bausch Health Cos Competitors Organon & Co. Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GYRE) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
